Clinical trials: Hepatic Tumors
Liver Cancer
Evaluation of Image-Guided Liver Surgical System for Resection of Liver Cancer
Image-guided surgery essentially describes the interactive use of medical images during a surgical procedure and is often referred to as a "global positioning" system (GPS) for surgery.
- Trial name
- NCT00782886
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- Pathfinder Therapeutics
Hepatic Tumor
Multicenter Study to Evaluate a New Robotic Device for Image-guided Percutaneous Needle Placement
This study evaluates the safety and performance of a new robotic device in the treatment of hepatic thermoablation in adults. The new robotic device will be used in all patients.
- Trial name
- NCT04230642
- Testing
- The Quantum Surgical device
- Where
- 2 sites in France
- Volunteers
- 22 people
- Sponsor
- Quantum Surgical
Hepatocellular Carcinoma
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
- Trial name
- ATHENA (NCT06084884)
- Testing
- AZD5851
- Where
- 19 sites in United States, Japan and 1 more
- Volunteers
- 94 people
- Sponsor
- AstraZeneca
Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC)
A Study of SH009 Injection in Patients With Advanced Solid Tumors.
Evaluate the efficacy and safety of SH009 injection therapy for patients with advanced solid tumors
- Conditions
- Liver Cancer (Locally Advanced or Metastatic), Lung Cancer (NSCLC), Head and Neck Cancer Squamous Cell Carcinoma, Breast Cancer (Locally Advanced or Metastatic)
- Trial name
- NCT07390838
- Testing
- SH009
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to…
- Conditions
- Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06084481
- Testing
- ABBV-400, Itraconazole (ITZ), Bevacizumab
- Where
- 54 sites in United States, Australia and 6 more
- Volunteers
- 325 people
- Sponsor
- AbbVie
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo
Hepatic Encephalopathy
A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) [The RETRO Study]
This is a retrospective study in adult patients with cirrhosis and grade 3 or 4 HE (West Haven Criteria) to evaluate the effectiveness and safety of lactulose retention enema in the treatment of deep grade HE (West Haven…
- Trial name
- NCT02377947
- Where
- 3 sites in India
- Volunteers
- 50 people
- Sponsor
- Abbott
Advanced Hepatocellular Carcinoma
Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
The purpose of this study of capmatinib (INC280) and spartalizumab (PDR001) was to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of spartalizumab administered…
- Trial name
- NCT02795429
- Testing
- Spartalizumab, Capmatinib
- Where
- 17 sites in Canada, China and 6 more
- Volunteers
- 89 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Hepatocellular Carcinoma
Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)
To compare the efficacy of Transarterial Chemoembolization (TACE) to CyberKnife stereotactic body radiotherapy in the treatment of patients with locally recurrent hepatocellular carcinoma (HCC) after TACE.
- Trial name
- NCT01318200
- Testing
- Transarterial Chemoembolization, CyberKnife SBRT
- Where
- United States
- Sponsor
- Accuray Incorporated
Advanced Hepatocellular Carcinoma
Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.
- Trial name
- SIERRA (NCT05883644)
- Testing
- Durvalumab, Tremelimumab
- Where
- 40 sites in United States, France and 8 more
- Volunteers
- 111 people
- Sponsor
- AstraZeneca
Melanoma (Skin), Metastatic Cancer
Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. Histamine dihydrochloride may help interleukin-2 kill more tumor cells by making tumor cells more sensitive to the drug.
- Trial name
- NCT00039234
- Testing
- aldesleukin, histamine dihydrochloride
- Where
- 19 sites in United States, Canada and 2 more
- Sponsor
- Maxim Pharmaceuticals
HCC, Hepatitis B Virus Related Hepatocellular Carcinoma
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.
- Conditions
- HCC, Hepatitis B Virus Related Hepatocellular Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT06617000
- Testing
- SCG101
- Where
- 7 sites in China
- Volunteers
- 38 people
- Sponsor
- SCG Cell Therapy Pte. Ltd.
HCC
A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.
This phase I/II clinical trial aims to determine the efficacy and safety of TATE compared to TACE in patients with intermediate-stage HCC.
- Trial name
- NCT06844357
- Testing
- tirapazamine, Transarterial Embolization (TAE), TACE
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Zhejiang Raygene Pharmaceuticals Co., Ltd
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
Hepatocellular Carcinoma, Hepatoma
A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma
This is a prospective, multicenter study that will be conducted at up to 40 centers in the United States and Outside United States (OUS).
- Conditions
- Hepatocellular Carcinoma, Hepatoma, Liver Cell Carcinoma
- Trial name
- SOLACE (NCT02460991)
- Testing
- DEB-TACE, Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Boston Scientific Corporation
HCC, Hepatocellular Carcinoma
LifePearl-Doxo Pharmacokinetic (PK) Study
The primary purpose of the study is to evaluate the pharmacokinetic profile, safety, and efficacy of LifePearl™ microspheres loaded with Doxorubicin in the treatment of unresectable HCC.
- Trial name
- NCT02548780
- Testing
- Chemoembolization, Pharmacokinetics
- Where
- 3 sites in Greece, Spain and 1 more
- Volunteers
- 15 people
- Sponsor
- Terumo Europe N.V.
Neoplasms, Liver
A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma
The primary purpose of this study is to determine the maximum tolerable dose (MTD) and/or the maximum feasible dose (MFD), as well as to evaluate the safety of JX-594 (Pexa-Vec) injected within hepatic carcinoma tumors.
- Trial name
- NCT00629759
- Testing
- JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
- Where
- South Korea
- Volunteers
- 14 people
- Sponsor
- Jennerex Biotherapeutics
Hepatocellular Carcinoma (HCC)
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
A Trial to Evaluate the Efficacy and Safety of Camrelizumab Plus Rivoceranib (Apatinib) Versus Active Surveillance as Adjuvant Therapy in Patients with Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative…
- Trial name
- NCT04639180
- Testing
- Camrelizumab, Rivoceranib (Apatinib)
- Where
- 6 sites in China
- Volunteers
- 687 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Hepatocellular Carcinoma, Advanced Cancer
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines.
- Trial name
- NCT05257590
- Testing
- Nivolumab Injection [Opdivo], CVM-1118
- Where
- 5 sites in Taiwan
- Volunteers
- 95 people
- Sponsor
- TaiRx, Inc.